97 Federal Cases Alleging Cancer From Diabetes Drugs Centralized In MDL

97 Federal Cases Alleging Cancer From Diabetes Drugs Centralized In MDL

WASHINGTON, D.C. - Ninety-seven federal lawsuits in which plaintiffs allege that three incretin-based diabetes drugs caused their pancreatic cancer were centralized Aug. 26 by a federal judicial panel into a multidistrict litigation in the U.S. District Court for the Southern District of California (In Re: Incretin Mimetics Products Liability Litigation, MDL Docket No. 2452, JPMDL).

Find full version on lexis Advance®
Access this news story on lexis.com®